South Africa secures Europe-backed $90 million vaccine plant deal amid hantavirus outbreak fears, 7,000 jobs expected

South Africa has secured a R1.5 billion ($90 million) financing package between vaccine producer Biovac and the European Investment Bank to build what is being positioned as Africa’s first fully integrated end to end vaccine manufacturing plant, amid recent hantavirus outbreak concerns.

• South Africa secured a R1.5 billion deal with the European Investment Bank and Biovac to build Africa’s first fully integrated end-to-end vaccine manufacturing plant.
• The facility, set for completion by 2028, will produce oral cholera vaccines initially, later expanding to polio, pneumonia, and meningitis vaccines.
• The project strengthens economic ties with the European Union as South Africa diversifies partnerships amid strained relations with the United States.
• South Africa’s cabinet also highlighted a swift hantavirus response, emphasizing the nation’s strong disease surveillance and medical expertise.

The agreement marks a major step in Africa’s push to reduce dependence on imported vaccines after the Covid 19 pandemic exposed weaknesses in global pharmaceutical supply chains.

It also comes amid renewed focus on infectious disease preparedness following the recent hantavirus outbreak linked to a luxury expedition cruise ship, where three passengers, including two critically ill individuals, were evacuated from Cape Verde to Europe for specialist treatment.

At the same time, the deal reflects Pretoria’s deepening economic and strategic ties with the European Union as relations with the United States remain strained following months of diplomatic and trade tensions.

Africa’s vaccine ambitions gain momentum

Cabinet said the facility, scheduled for completion by 2028, will initially produce oral cholera vaccines before later expanding into vaccines for polio, pneumonia and meningitis.

Once fully operational, the plant is expected to produce up to 40 million doses annually, significantly strengthening Africa’s healthcare resilience and supply-chain security.

Although Africa already hosts several vaccine manufacturing facilities and projects, most operate on a smaller scale than plants in Europe, India and China and remain heavily dependent on imported ingredients for final filling and packaging.

The Biovac project is being positioned as Africa’s first fully integrated end-to-end multi-vaccine manufacturing facility, allowing more stages of vaccine development and production to take place locally as the continent pushes to strengthen pharmaceutical independence.

In line with that ambition, the project supports the Africa Centres for Disease Control and Prevention’s target for the continent to produce 60% of its vaccine needs locally by 2040.

The investment is also expected to create more than 340 skilled jobs and around 7,000 indirect jobs while further supporting technology transfer, pharmaceutical innovation and long-term healthcare resilience across the continent.

South Africa turns further toward Europe

The financing package reinforces Europe’s growing role in Africa’s healthcare and industrial ambitions as several African governments seek to diversify strategic partnerships beyond traditional Western allies.

Pretoria’s relationship with Washington has yet to fully recover following tensions over trade, foreign policy positioning and South Africa’s stance on several global conflicts.

Analysts say the strain has accelerated South Africa’s efforts to deepen economic engagement with the European Union, China and other partners less likely to pressure Pretoria diplomatically.

The vaccine project also arrives at a difficult moment for South Africa’s economy, which continues to face sluggish growth, weak manufacturing activity, persistent unemployment and infrastructure bottlenecks.

Government highlights hantavirus response

Alongside the vaccine announcement, South Africa’s cabinet praised the National Institute for Communicable Diseases for diagnosing two hantavirus cases within 24 hours after patients from the MV Hondius cruise ship were admitted to a Gauteng hospital.

Cabinet also commended the Department of Health for rapidly conducting contact tracing before the diagnosis was confirmed.

The government sought to calm fears of a wider outbreak, saying scientists had confirmed that hantavirus has not been detected in rats in South Africa or elsewhere on the African continent despite concerns linked to rodent infestations in some municipalities.